Immatics Announces Completion of Business Combination and Listing on NASDAQ

Nachrichtenquelle: globenewswire
02.07.2020, 13:00  |  362   |   |   

Houston, Texas and Tuebingen, Germany, July 02, 2020 (GLOBE NEWSWIRE) --

  • The business combination transaction with Arya Sciences Acquisition Corporation, a special purpose acquisition company sponsored by Perceptive Advisors, was completed on July 1, 2020
  • The combined company was renamed Immatics N.V.
  • Immatics common stock and warrants will commence trading today on the Nasdaq Capital Markets under the ticker symbols “IMTX” and “IMTXW”, respectively
  • Proceeds from this transaction were approximately $250 million, combining funds held in Arya’s trust account and a concurrent PIPE financing

Houston, Texas and Tuebingen, Germany, July 2, 2020 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced the completion of its business combination with Arya Sciences Acquisition Corp. (NASDAQ: ARYA; or “Arya”), a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. Today, Immatics N.V. will commence trading its shares under the symbol “IMTX” and its warrants under the symbol “IMTXW” on the Nasdaq Capital Market. Proceeds from this transaction were approximately $253 million, which included funds held in Arya’s trust account and the common stock private investment in public equity (PIPE) financing contributed by a group of leading US healthcare institutional investors. The shareholders of Arya approved the transaction on June 29, 2020, and none of Arya’s shareholders redeemed their shares in connection with the ARYA shareholder approval. The transaction had been previously approved by Immatics shareholders. Immatics’ management team, led by Chief Executive Officer Harpreet Singh, Ph.D., will continue to run the combined company.

Harpreet Singh, Ph.D., Co-Founder and CEO of Immatics, commented: “I would like to thank the team at Immatics, our partners at Perceptive, existing Immatics and Arya shareholders, the PIPE investors, and all our advisors for making this transaction a success. It will provide us runway and flexibility for our pursuit of unlocking new therapeutic options for cancer patients by advancing our clinical and pre-clinical programs for Adoptive Cell Therapies and TCR Bispecifics. Our programs are directed against a range of targets that address multiple rare as well as common cancers that have been hard to treat.”

Seite 1 von 5
Immatics Aktie jetzt ab 0€ handeln - auf Smartbroker.de

Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel

Diskussionen zu den Werten

ZeitTitel
14.08.20